Table 1. Descriptive Characteristicsa.
| Characteristic | Screening group (n = 30 336) | Control group (n = 48 270) | ||
|---|---|---|---|---|
| Statin users | Statin nonusers | Statin users | Statin nonusers | |
| No. of participants (n = 30 336) | 12 059 | 18 277 | 19 567 | 28 703 |
| Person-years | 179 441 | 231 251 | 293 675 | 369 184 |
| Baseline characteristics | ||||
| Age at randomization, median (IQR), y | 59 (55-63) | 59 (55-63) | 59 (55-63) | 59 (55-63) |
| Duration of follow-up until PCa diagnosis, median (IQR), y | 17 (13-19) | 17 (9-19) | 17 (14-19) | 17 (9-18) |
| Duration of follow-up until death, median (IQR), y | 18 (16-19) | 17 (12-19) | 18 (17-19) | 17 (11-19) |
| BMI, median (IQR)b | 27.4 (24.3-29.7) | 26.4 (23.9-28.4) | NA | NA |
| Employed, No. (%)c | 5885 (48.8) | 8421 (46.1) | 9433 (48.2) | 13 249 (46.2) |
| Screening characteristics | ||||
| Median (IQR) PSA level, ng/mL | 1.18 (0.68-2.14) | 1.28 (0.74-2.41) | NA | NA |
| Compliance to screening 1st round, No. (%) | 8970 (74.4) | 11 814 (65.0) | NA | NA |
| Positive screening result, No. (%) | 619 (5.1) | 1358 (7.4) | NA | NA |
| Screen-positive men who subsequently had prostate biopsy, No. (%) | 578 (93.4) | 1299 (95.7) | NA | NA |
| Proportion of men with any opportunistic PSA screening before 1st study screening, No. (%) | 476 (3.9) | 689 (3.8) | 671 (3.4) | 880 (3.1) |
| Outcomes | ||||
| PCa diagnoses during follow-up, No. (%) | 1072 (8.9) | 2600 (14.3) | 1718 (8.8) | 3172 (11.1) |
| PCa rate per 1000 person-years | 6.0 | 11.2 | 5.9 | 8.6 |
| PCa mortality, No. (%) | 75 (0.6) | 212 (1.2) | 125 (0.6) | 372 (1.3) |
| PCa mortality rate per 1000 person-years | 0.4 | 0.9 | 0.4 | 1.0 |
| All deaths, No. (%) | 2933 (24.3) | 5846 (32.0) | 4652 (23.8) | 9764 (34.0) |
| Death rate per 1000 person-years | 16.3 | 25.3 | 15.8 | 26.4 |
Abbreviation: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); NA, not applicable; PCa, prostate cancer; PSA, prostate-specific antigen.
a
Study population of 78 606 men from the Finnish Randomized Study of Screening for Prostate Cancer.
b
BMI available for 11 698 men in the screening group.
c
Men who were employed, students, or entrepreneurs.